Professional obligations to curb the prevalence of cigarette smoking reflect the importance of this preventable risk factor for innumerable diseases. These include chronic obstructive pulmonary disease and oral, lung and other cancers, although the morbidity and mortality rates for cerebrovascular disease (e.g., ischemic strokes) and cardiovascular disease (e.g., ischemic myocardial infarction) tend to be greater. Various alternative nicotine sources (e.g., transdermal nicotine patches, nicotine gum, nicotine nasal sprays) have been incorporated into smoking cessation programs. This review is intended to increase professional awareness of nicotine delivery systems available in Canada, including safety considerations. The pathogenic potential of nicotine, regardless of source, and the contraindications to the use of nicotine replacement therapies are discussed. However, the systemic nicotine load in individuals undergoing replacement therapy is generally lower than during active smoking. Nicotine is only one of many thousands of constituents of tobacco smoke. Furthermore, nicotine replacement is usually delivered over the short term (a matter of weeks). Therefore, nicotine replacement is recognized as a relatively safe and effective aid to smoking cessation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Smoking is a significant public health issue in Tamil Nadu, causing preventable diseases and increasing healthcare costs, necessitating effective smoking cessation strategies in primary health care (PHC) settings.
- The study aims to evaluate the cost-effectiveness of three proposed smoking cessation strategies against the current standard strategy, focusing on various combinations of counseling, nicotine replacement therapy, and medications for smokers aged 15 and older.
- Results indicated that the current cessation strategy was more expensive than the proposed strategies, with two of them (PS1 and PS3) being more cost-effective, potentially leading to better resource allocation for smoking cessation efforts.
Electronic cigarettes for smoking cessation.
Cochrane Database Syst Rev
January 2025
Department of Health Promotion and Policy, University of Massachusetts, Amherst, MA, USA.
Background: Electronic cigarettes (ECs) are handheld electronic vaping devices that produce an aerosol by heating an e-liquid. People who smoke, healthcare providers, and regulators want to know if ECs can help people quit smoking, and if they are safe to use for this purpose. This is a review update conducted as part of a living systematic review.
View Article and Find Full Text PDFCytisine compared to combination nicotine replacement therapy to reduce cigarette consumption in relapsed smokers: protocol for a pilot randomized controlled trial.
Pilot Feasibility Stud
January 2025
University of Ottawa Heart Institute, Ottawa, Canada.
Background: Cigarette smoking is a leading cause of death and disease, including those related to the cardiovascular system. Cytisine is a plant-based medication, which works in a similar mechanism to varenicline. It is safe, efficacious, and cost-effective for smoking cessation.
View Article and Find Full Text PDFAttitude, Practice and Perceived Barrier for Tobacco Cessation Counseling and Nicotine Replacement Therapy among Private Dental Practitioners of North India: A Web based Survey.
Asian Pac J Cancer Prev
January 2025
Department of Dentistry, Adesh Institute of Dental Sciences And Research, Bathinda, India.
Objective: To assess the attitude and practices towards the Tobacco Cessation Counselling and Nicotine Replacement Therapy and identify the possible barriers towards the implementation of these practices amongst Private dental practitioners of North, India. Methodology: A cross sectional web based survey using 33 item pre-tested self administered questionnaire was conducted. A total of 250 valid responses were received and were available for analysis.
View Article and Find Full Text PDFDifferences in the effectiveness of individual-level smoking cessation interventions by socioeconomic status.
Cochrane Database Syst Rev
January 2025
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Background: People from lower socioeconomic groups are more likely to smoke and less likely to succeed in achieving abstinence, making tobacco smoking a leading driver of health inequalities. Contextual factors affecting subpopulations may moderate the efficacy of individual-level smoking cessation interventions. It is not known whether any intervention performs differently across socioeconomically-diverse populations and contexts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!